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Hepatitis C virus (HCV) can cause liver disease of variable severity. Expansion of preexisting 
memory CD8 T cells by cross-reactivity with a new heterologous virus infection has been 
shown in mice to shape the repertoire of the primary response and to influence virus-related 
immunopathology (Selin, L.K. 2004. 
 
Immunity
 
. 20:5–16). To determine whether this 
mechanism can influence the course of HCV infection, we analyzed the features of the 
HCV-specific CD8 T cell response in eight patients with acute HCV infection, two of whom 
had a particularly severe illness. Patients with severe hepatitis, but not those with mild 
disease, showed an extremely vigorous CD8 T cell response narrowly focused on a single 
epitope (NS3 1073–1081), which cross-reacted with an influenza neuraminidase sequence. 
Our results suggest that CD8 T cell cross-reactivity influences the severity of the HCV-
associated liver pathology and depicts a model of disease induction that may apply to 
different viral infections.
 
Hepatitis C virus (HCV) is believed to infect
 
 
 
170 million people worldwide and represents
one of the leading causes of liver disease, which
is sustained primarily by the immune response
to HCV. The majority of HCV-infected people
develop chronic hepatitis, and the acute phase
of infection is frequently asymptomatic. Clinical
symptoms are present in approximately one
third of acute infections acquired as an adult
and are extremely heterogeneous, as is the case
with many other human viral infections. They
are generally mild, but some cases of hepatitis
C can run an extremely severe course that is
noted with a marked elevation of serum en-
zymes, which is indicative of liver cell damage
(alanine aminotransferase [ALT]), and with
clear signs of a loss of hepatic function (e.g.,
elevated bilirubin and prolonged prothrombin
time; references 1, 2). Unfortunately, the
mechanisms responsible for these different
courses and outcomes are unknown. Differ-
ences in the infection dose, viral strain, and
genetic make-up of the host have been used to
explain such variability. A further possibility is
that the variability in the pathology caused by
viral infections strictly reflects different profiles
of T cell immunodominance and different
kinetics of T cell responses. This phenomenon
has been demonstrated in mice, and it is caused
by the presence of a large repertoire of memory
T cells from earlier infections that can cross-
react with a second infecting viral pathogen,
which leads to a massive recruitment of preex-
isting memory cells into a primary immune
response (3–6).
In this paper, we report an association
between a peculiar hierarchy of immunodom-
inance of HCV-specific CD8 responses, cross-
reactivity between HCV- and influenza-specific
CD8 cells and a severe clinical course of hepa-
titis C. Our results suggest a role for CD8
cross-reactivity in influencing the severity of
the HCV-associated liver pathology and de-
picts a model of disease induction that may
apply to different viral infections in which
immunopathology is sustained by the antiviral
immune response.
 
RESULTS AND DISCUSSION
 
To characterize HCV-specific CD8 T cell–
mediated responses associated with severe liver
pathology in acute HCV infection, we ana-
lyzed the global profile of the HCV-specific T
cell response in eight patients who showed
variable outcomes of acute HCV infection
(Fig. 1 A). Two individuals (Fig. 1 A, patients
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1 and 2) that were infected with genotype 1b HCV showed
a severe clinical course of acute hepatitis C with rapidly ris-
ing bilirubin levels, elevated ALT values, and prolonged
prothrombin time (Fig. 1, B and C). Six patients (patients 3–8)
that were also infected by genotype 1 HCV displayed a mild
course of liver disease, as generally observed after HCV infec-
tion (Fig. 1). A comprehensive analysis of the HCV-specific
T cell repertoire was performed using a panel of 601 15-mer
Figure 1. Characteristics of the population of patients with acute 
hepatitis C. (A) Clinical and virological features of the eight patients with 
acute HCV infection studied. (B) Sequential evaluation of serum ALT levels 
from the time of clinical presentation. (C) Behavior of serum ALT levels (closed 
squares), prothrombin activity (open squares), and quantitative (open circles) 
and qualitative HCV-RNA and anti-HCV antibodies in patient 1.
Figure 2. IFN-  production by direct ex vivo ELISPOT analysis. 
PBMCs from patients with severe course (A, patients 1 and 2) and with 
mild course (B, patients 3–5 and 8) of acute HCV infection were stimulated 
overnight with 119 pools of overlapping 15-mer peptides covering the 
whole HCV sequence. ELISPOT analysis was performed when the patients 
first reported to the clinics (Fig. 1 B, day 1). (C) Longitudinal analysis of the 
T cell response to the 119 pools of overlapping peptides performed in 
patients 1 and 8 at the indicated weeks after the time of exposure to HCV 
that was precisely identified. (D) The same sequential study was performed 
in patients 3 and 5 at the indicated weeks after the first presentation in 
the clinics (unknown time of infection). 
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peptides overlapping by 10 residues and spanning the entire
HCV sequence of genotype 1a. Direct ex vivo frequency of
IFN-
 
 
 
–producing T cells was evaluated in patients 1–5 and
8 (Fig. 2, A and B) in the acute phase of infection at the peak
of ALT. A dramatic difference in the T cell repertoire was
evident in the two patient populations. Although T cell re-
sponses were narrowly focused on a few peptide pools in
patients 1 and 2 (Fig. 2 A), simultaneous recognition of mul-
tiple HCV sequences was detected in patients 3–5 and 8
(Fig. 2 B), as previously described in recovered and acutely
infected patients (7–9). 
Of the 119 mixtures of synthetic peptides tested, 34 in
patient 3, 33 in patient 4, 18 in patient 5, and 12 in patient 8
were able to induce IFN-
 
 
 
 production. These broad T cell
responses were directed toward all viral antigens and differ-
ent peptide mixtures induced responses of different intensity,
ranging from 50 to 1,100 spot-forming cells (SFC)/10
 
6
 
 PBMCs
in patient 3, from 500 to 3,700 in patient 4, from 50 to 920
in patient 5, and from 45 to 1,000 in patient 8. Further anal-
ysis performed by ICS to identify the individual epitopes
showed that many peptides were recognized by patients 3–5
and 8. The responses were sustained by a mixed activation of
both CD4 and CD8 T cell subsets (unpublished data). In
contrast, only a single sequence containing the previously
described HLA-A2–restricted NS3 1073–1081 CD8 epitope
(10) was identified in patients 1 and 2. The profound immu-
nodominance of NS3 1073–1081–specific CD8
 
 
 
 T cells in
these HLA-A2
 
 
 
 patients was confirmed by direct ex vivo
tetramer staining for five distinct HCV epitopes (11–14).
Confirming the data obtained with ELISPOT, both patients
showed extremely elevated frequencies of NS3 1073–1081-
specific CD8 T cells, whereas other specificities were nega-
tive also using peptides of optimal length for CD8 T cell
recognition and corresponding to well-characterized HLA-
A2–restricted epitopes. NS3 1073–1081 tetramer
 
 
 
 CD8 T
cells reached values of 36 and 12% of the total CD8 T cells
in patients 1 and 2 (Fig. 3 A). These frequencies were much
higher than those previously reported in acute HCV infec-
tion (15–17) and those detected in three subjects with mild
course of infection who were analyzed for comparison (Fig.
3 B). The phenotypic analysis of the tetramer
 
 
 
 cells in the
five patients showed an identical maturation stage (effector-
memory stage). Almost all tetramer
 
 
 
 cells were CCR7
 
 
 
,
CD45RA
 
 
 
, and CD27
 
 
 
, and predominantly HLA-DR
 
 
 
and CD69
 
 
 
 (unpublished data).
The different breadth of the CD8 T cell response in patients
with severe and milder courses of the disease may reflect the
different times after infection at which individual patients
were studied. To exclude this possibility, we analyzed HCV-
specific T cell responses longitudinally in patient 1 (severe
hepatitis) and in patient 8 (milder disease). The precise time
of infection was known in both, allowing us to perform a
complete sequential analysis of the CD8 T cell response (Fig.
2 C). In patient 1, CD8 T cell responses were already positive,
extremely vigorous, and narrowly focused on a single epitope
3 wk after infection. Except for a marginal and transient
broadening on week 8, the response remained focused on
the NS3 sequence 1073–1081 throughout the follow-up
(from week 3 to 24). In contrast, the CD8 T cell response
became detectable later in patient 8 (Fig. 2 C); it was widely
multispecific with simultaneous recognition of multiple
epitopes at the time of the first positive assay (week 11) and a
comparable breadth of the response was maintained thereaf-
ter (week 16). The behavior of patient 8 was consistent with
the responses in patients 3 and 5 with milder disease (Fig. 2 D),
in whom the precise time of infection could not be estab-
lished. Their CD8 T cell response was multispecific at the
first determination and the breadth of response remained
similar throughout the follow-up. Therefore, HCV-specific
CD8 T cell–mediated responses in subjects who displayed
different clinical courses of acute hepatitis C showed clear
differences in their T cell repertoire. A strong dominance of
a single HCV-specific CD8 T cell response was detected in
patients with severe hepatic damage, whereas a milder dis-
ease was associated with a broader repertoire of the HCV-
specific T cell response.
A possible interpretation of these results is that the dra-
matic expansion of NS3 1073–specific CD8 T cells in patients
Figure 3. Peripheral blood frequency of HCV-specific CD8 T cells 
by ex vivo tetramer staining. (A) Dot plot analysis of HCV NS3 1073 
tetramer  CD8 T cells in patients 1 and 2. (B) Percentage of tetramer  
CD8 T cells specific for five HCV epitopes corresponding to NS3 1073, NS3 
1406, NS4 1812, NS4 1992, and NS5 2627 detected ex vivo in PBMCs of 
five HLA-A2  patients with acute HCV infection at the time of presenta-
tion in the clinics (Fig. 1 A, patients 1–3, 6, and 7). All plots illustrate the 
results obtained at the first time the patients reported to the clinic. 
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1 and 2 was related to the presence of a private repertoire of
memory T cells able to cross-react with the HCV sequence.
The high degree of homology reported between HCV NS3
1073–1081 and influenza NA 231–239 sequences (10) sup-
ports this possibility. Moreover, T cell cross-reactivity be-
tween these two HCV and influenza sequences was observed
in humans (HCV-infected patients and healthy HCV-unin-
fected subjects) and in HLA-A2
 
 
 
 transgenic mice (10). In
addition, severe immunopathology after viral infection was
shown to be caused in mice by the expansion of memory T
cells from an earlier infection that cross-reacted with a second
unrelated heterologous virus (3–6). Homology of the NS3
1073–1081 and the influenza NA 231–239 sequences was
confirmed in our study by sequence analysis of the NS3 re-
gion performed on individual cDNA clones (18) in the pa-
tients with severe liver pathology (patients 1 and 2). Further-
more, database analysis indicates that the influenza NA 231–239
epitope is highly conserved among the published influenza
sequences of H1N1 and H3N2 subtypes that are the only in-
fluenza subtypes isolated during the last 15 yr in the geo-
graphical region where the patients lived.
To determine whether potentially cross-reactive CD8 T
cells were present in patients with severe liver pathology,
direct ex vivo IFN-
 
 
 
 ELISPOT analysis was performed in
patients 1 and 2 (severe liver pathology) and in patients 6 and 7
(milder disease) for comparison. Although all patients showed a
flu matrix 58–66–specific CD8 T cell response, demonstrating
prior sensitization to influenza, NA 231 influenza–specific cells
were detected exclusively in patients 1 and 2 (Fig. 4 A).
Next, functional experiments were performed to assess
whether NS3 1073–specific CD8
 
 
 
 T cells in patients 1 and 2
could be activated by the NA 231–239 sequence. Ex vivo
analysis showed that NA 231–239 peptide stimulation elic-
ited up-regulation of CD107a expression (Fig. 4 B; reference
19) and IFN-
 
 
 
 production (Fig. 4 C) selectively among NS3
1073–1081 tetramer
 
 
 
 cells, but not among the tetramer
 
 
 
CD8 T cell subset.
In keeping with ex vivo experiments, cross-recognition of
HCV NS3 1073 and flu NA 231 peptides was observed in
NS3-specific and flu NA–specific T cell lines derived from pa-
tients 1 and 2 but not in NS3-specific lines derived from pa-
tients 3 and 7 (Fig. 4 D). Furthermore, IFN-
 
 
 
 production
upon NA 231–239 peptide stimulation was restricted to the
NS3 1073–1081 tetramer
 
 
 
 CD8 fraction of the NS3-specific
lines in patient 1 (Fig. 4 D). Finally, cytotoxicity experiments
performed using HCV NS3 1073–specific T cell lines derived
from patients 1 and 3 confirmed the selective presence of cross-
reactivity in patients with severe liver pathology (Fig. 4 E).
Figure 4. Recognition of HCV NS3 1073 and flu NA 231 peptides 
by HCV NS3–specific CD8 T cells. (A) Ex vivo IFN-  ELISPOT analysis. 
PBMCs from four HLA-A2  patients with acute HCV infection were stim-
ulated overnight with the peptides NS3 1073, flu NA 231, and flu Matrix 
58. The results are expressed as change in spot-forming cells ( SFC) per 
106 PBMCs. (B and C) CD107a expression and of IFN-  production by ICS 
analysis ex vivo. PBMCs from patients 1 and 7 were incubated for 2 h 
(CD107a expression) or 4 h (IFN-  production) with HCV NS3 1073, flu 
NA231, flu MA 51 peptides, or medium alone. (B) Histograms represent 
CD107a expression in gated HCV NS3 tetramer  CD8 T cells at the indicated 
experimental conditions. (C) Plots represent IFN-  production in gated 
tetramer  (top) or tetramer  (bottom) HCV NS3 1073 cells. (D) IFN-  
production in NS3- and Flu-specific T cell lines by ICS analysis. T cell lines 
produced by 10-d stimulation with the NS3 1073 or the flu NA 231 pep-
tides (top) were stimulated for 4 h in medium alone, with the HCV NS3, 
with the flu NA, or with a control HLA-A2–restricted MAGE peptide (MAGE 
271–279; FLWGPRALV). Numbers at the top of the bars indicate the per-
centage of IFN- –positive CD8 T cells. NS3 1073–specific T cell lines from 
patients 1 and 7 (bottom) were stimulated at the indicated experimental 
conditions. Plots are gated on HCV 1073 tetramer  CD8 T cells. The num-
bers indicated in each plot represent the percentage of IFN- –positive 
cells among the HCV NS3 tetramer  CD8 T cell population. No IFN-  pro-
duction was detectable in patient 1 upon stimulation with the flu NA 231 
peptide in NS3 tetramer  CD8 T cells (not depicted). (E) Cytotoxic activity 
of HCV NS3 1073–specific T cell lines produced by 10-d stimulation with 
the NS3 1073 peptide in patients 1 and 3 against HLA-A2  target cells 
(E/T ratio   40:1) incubated in medium alone or pulsed either with the 
HCV NS3 1073 peptide or with the Flu NA 231 peptide or with a control 
MAGE peptide. Each bar shows the percentage of 51Cr release at the differ-
ent experimental conditions described above. 
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Together, these data show that although sensitization to
influenza is a very common event, the individual private
repertoire of memory T cells seems to be the limiting factor
for cross-reactivity between HCV and influenza to occur. A
private T cell repertoire of HCV/influenza cross-reactive T
cells was present exclusively in the patients with severe he-
patic immunopathology. In this setting, reactivation of pre-
existing influenza-specific memory CD8
 
 
 
 T cells by a pri-
mary HCV infection may have resulted in the strong
immunodominance of the NS3 1073–specific CD8
 
 
 
 T cell
response present in these two patients. Notably, the kinetics
of expansion and contraction of HCV-specific CD8
 
 
 
 T cell
responses in patient 1 further supports the possibility that
memory CD8
 
 
 
 T cells able to cross-react with the HCV
NS3 1073 sequence were actually present. In this patient, a
massive expansion (36%) of NS3 1073–specific CD8
 
 
 
 T
cells was already detectable as early as 2–3 wk from the time
of a previous hospitalization, which likely corresponds to the
time of infection. In contrast, other HCV-specific CD8
 
 
 
 T
cells (against the NS5 sequence 1992–2000) increased their
frequency at later time points, when the NS3 1073–specific
response was already in a contracting phase (Fig. 5). Because
memory T cells exhibit a more rapid response than naive T
cells, the differential kinetics of HCV-specific CD8 T cells
specific for different epitopes located in nonstructural pro-
teins further supports the view that NS3 1073 cross-reactive
memory T cells were present before HCV infection. This
rapid appearance of NS3 1073–specific T cell responses is
also different from the kinetics reported in patients acciden-
tally infected by needlestick exposure to HCV positive
blood (17) and in primary infection of chimpanzees (20) in
which HCV-specific T cell responses were detectable only
 
 
 
2 mo after infection.
In conclusion, our findings provide a unique example of
how the course of the pathology associated with primary
HCV infection can be profoundly influenced by the virus-
specific CD8 T cell repertoire elicited in the individual
subjects. As shown in mice (3–6), it is possible that previous
infection and the presence of cross-reactive T cells between
different viruses is responsible for the marked immuno-
dominance present in subjects with severe hepatic disease.
Although NS3-specific CD8 T cells expanded rapidly
and vigorously, the virus was not efficiently controlled and
liver pathology was severe. HCV chronicity could not be at-
tributed, at least in patient 2, to the development of escape
mutants because in this subject a longitudinal analysis of the
NS3 1073 sequence was performed over a 9-mo period and
mutations within this region were not found. Thus, a robust,
but isolated, response to the NS3 1073 epitope seems inade-
quate for viral control. A poor CD4 T cell response may
have contributed to the lack of antiviral efficacy of the NS3-
specific CD8 T cell response (21). Alternatively, the absence
of a concomitant multispecific CD8 T cell response might
be implicated in the inability to control HCV. The inability
of NS3-specific CD8
 
 
 
 T cells to efficiently control viral
replication within the liver may have also contributed to the
severity of liver cell damage. Intrahepatic activation of a
large quantity of HCV-specific CD8 T cells with poor anti-
viral function might have sustained a massive recruitment of
nonspecific immune cells causing severe liver inflammation
(22). These findings are also a warning about the development
of antiviral vaccines. Focusing the CD8 T cell response on
single immunodominant epitope with poor antiviral efficacy
may have severe pathological consequences.
 
MATERIALS AND METHODS
 
Patients and virological assessment.
 
Eight patients with acute hepati-
tis C were enrolled at the Department of Infectious Diseases of the Univer-
sity Hospital of Parma. The diagnosis of acute HCV infection was based on
documented seroconversion to anti-HCV antibodies by RIBA assay, levels
of serum ALT at least 10 times the upper limit of normal (50 U/l), detec-
tion of HCV RNA, exclusion of other possible causes of acute hepatitis.
For two patients (patients 1 and 8), the precise time of infection could be
precisely determined. Patient 1 developed jaundice and became symptom-
atic 3 wk after a previous hospitalization, during which he was treated with
parenteral infusions of glucose and saline solutions. Anti-HCV antibodies
were negative and ALT levels were normal at that time, indicating that in-
fection was acquired during hospitalization. Patient 8 had an accidental ex-
posure to HCV-infected blood; he was anti-HCV antibody negative and
HCV-RNA negative at the time of the parenteral exposure. Anti-HCV an-
tibodies were determined by commercial enzyme immunoassay kits (Ortho
Diagnostic Systems) and by RIBA (RIBA II; Ortho Diagnostic Systems).
Serum HCV-RNA was quantified by branched DNA assay (model
340bDNA Analyzer; Bayer Corporation); the lower limit of detection by
this method is 2,500 copies/ml. This study was approved by the Ethical
Committee of the Azienda Ospedaliero Universitaria di Parma, and all sub-
jects gave written, informed consent.
 
Synthetic peptides, peptide-HLA class I tetramers, and antibod-
ies.
 
Synthetic peptides representing the HLA-A2–restricted epitopes HCV
NS3 1073–1081 (CINGVCWTV), NS3 1406–1415 (KLVALGINAV),
NS4 1812–1820 (LLFNILGGWV), NS4B 1992–2000 (VLSDFKTWL),
NS5 2594–2602 (ALYDVVTKL), influenza virus NA 231–239 (CVNG-
SCFTV), and MA 58–66 (GILGFVFTL), and a panel of 601 15-mer pep-
tides overlapping by 10 residues and covering the overall sequence of
HCV-1 were purchased from Chiron Mimotopes. PE-labeled tetrameric
peptide–HLA class I complexes were purchased from Proimmune LTD.
Figure 5. Kinetics of HCV-specific CD8 T cell–mediated responses 
in patient 1 analyzed ex vivo by tetramer staining and ELISPOT assay. 
(A) Percentage of tetramer  CD8 T cells specific for HCV NS3 1073 (gray 
bars) and NS4 1992 (black bars) epitopes measured ex vivo at sequential 
time points from the time of infection. HCV viremia detected by branched 
DNA assay (lower limit of detection, 2,500 copies/ml) is also illustrated. 
(B) IFN-  production analyzed sequentially during the first 10 wk after 
infection by ELISPOT upon PBMC stimulation with NS3 1073 (gray line) 
and NS4 1992 (black line) peptides. The results are expressed as  SFC per 
106 PBMCs. 
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HLA A2 tetramers contained the HCV peptides NS3 1073–1081, NS3
1406–1415, NS4 1812–1820, NS4B 1992–2000, and NS5 2594–2602.
 
In vitro expansion of HCV-specific CD8 T cells.
 
PBMCs were re-
suspended in 96-well plates at a concentration 2 
 
 
 
 10
 
6
 
/ml and stimulated
with HCV peptides at a final concentration of 1 
 
 
 
M. Recombinant IL-2
was added on day 4 of culture (50 UI/ml) and the immunological assays
were performed on day 10.
 
Cell surface and intracellular staining, ELISA.
 
Staining with tetra-
mers and other surface markers and IFN-
 
 
 
 staining were performed as de-
scribed previously (15). 
 
ELISPOT assay.
 
601 15-mer peptides, based on a genotype 1a sequence
(HCV-1) covering all structural (core, E1, and E2) and nonstructural (NS3,
NS4, and NS5) HCV regions and overlapping by 10 residues, were pooled
in 119 mixtures, each containing 10 synthetic peptides. HCV-specific T cell
responses were analyzed upon overnight stimulation with individual peptide
mixtures. ELISPOT assay was performed as described previously (23). Plates
were counted using an automated ELISPOT reader (AID Elispot Reader
System; Autoimmune Diagnostika Gmbh). IFN-
 
 
 
–producing cells were ex-
pressed as SFC per 10
 
6
 
 cells. The number of specific IFN-
 
 
 
–secreting PB-
MCs was calculated by subtracting the unstimulated control value from the
stimulated sample. Unstimulated wells never exceeded five to seven spots per
well. Positive controls consisted of PBMCs stimulated with PHA. Wells
were considered positive if they were at least two times above background.
 
Chromium release assay.
 
Cytotoxic activity was assessed by incubating
peptide-stimulated PBMCs with peptide-pulsed 
 
51
 
Cr-labeled, HLA-A2–
matched EBV-transformed B cells as targets for 4 h in round-bottom 96-
well plates. Percent-specific lysis was calculated as described previously
(15). 
 
51
 
Cr released in the presence of culture medium ranged between 15
and 25% of total releasable counts. To adopt very stringent criteria and
avoid the risk of false positive results, only levels of CTL lysis 
 
 
 
13% were
considered significant.
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